- Home
- SISI vs ONVO Comparison
SISI vs ONVO Comparison
Compare SISI & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- ONVO
- Stock Information
- Founded
- SISI 1997
- ONVO 2007
- Country
- SISI China
- ONVO United States
- Employees
- SISI N/A
- ONVO N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SISI Health Care
- ONVO Health Care
- Exchange
- SISI Nasdaq
- ONVO Nasdaq
- Market Cap
- SISI 5.9M
- ONVO 6.5M
- IPO Year
- SISI 2016
- ONVO N/A
- Fundamental
- Price
- SISI $1.65
- ONVO $0.37
- Analyst Decision
- SISI
- ONVO
- Analyst Count
- SISI 0
- ONVO 0
- Target Price
- SISI N/A
- ONVO N/A
- AVG Volume (30 Days)
- SISI 613.8K
- ONVO 245.2K
- Earning Date
- SISI 02-06-2025
- ONVO 02-06-2025
- Dividend Yield
- SISI N/A
- ONVO N/A
- EPS Growth
- SISI N/A
- ONVO N/A
- EPS
- SISI N/A
- ONVO N/A
- Revenue
- SISI $10,330,284.00
- ONVO $103,000.00
- Revenue This Year
- SISI N/A
- ONVO $59.08
- Revenue Next Year
- SISI N/A
- ONVO $18.24
- P/E Ratio
- SISI N/A
- ONVO N/A
- Revenue Growth
- SISI 370.34
- ONVO N/A
- 52 Week Low
- SISI $1.63
- ONVO $0.32
- 52 Week High
- SISI $117.65
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- SISI 40.35
- ONVO 44.33
- Support Level
- SISI $1.66
- ONVO $0.35
- Resistance Level
- SISI $1.89
- ONVO $0.51
- Average True Range (ATR)
- SISI 0.34
- ONVO 0.05
- MACD
- SISI -0.03
- ONVO -0.00
- Stochastic Oscillator
- SISI 1.18
- ONVO 13.33
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.